Mirum Pharmaceuticals Conference Call Summary Company Overview - **Company**: Mirum Pharmaceuticals (NasdaqGM:MIRM) - **Focus**: Rare disease medicines, with a strategy centered on developing high-impact therapies for patients with rare diseases [4][5] Financial Performance - **Revenue Guidance**: Expected top line revenue for 2026 is between $630 million and $650 million, reflecting strong performance across three approved medicines [5][29] - **Growth Drivers**: The company anticipates four pivotal readouts over the next 18 months, indicating a pivotal year for growth [5][46] Product Pipeline and Commercial Opportunities LIVMARLI - **Indications**: Approved for Alagille syndrome and PFIC, with ongoing expansion into additional indications through the EXPAND study [8][30] - **Mechanism**: LIVMARLI reduces circulating bile acid levels, significantly alleviating symptoms such as pruritus in patients [8][9] - **Market Dynamics**: Steady growth in Alagille syndrome patient starts; PFIC adoption is dynamic due to increased genetic testing [10][13] - **Sales Growth**: LIVMARLI sales are expected to contribute significantly to the overall revenue, with projections indicating it could become a billion-dollar brand [45][94] Cholbam and CTEXLI - **Sales Performance**: Revenue for Cholbam and CTEXLI has grown to over $160 million, driven by increased awareness and diagnosis efforts [23][24] - **Market Strategy**: Focus on both raising awareness and identifying new patients for these rare conditions [24][26] Brelovitug - **Indication**: Targeting Hepatitis D, a rare and progressive liver disease with significant unmet need [52] - **Clinical Data**: Phase 2 data showed promising results, with a 100% virologic response at 48 weeks [57] - **Enrollment**: Rapid enrollment in registration studies indicates strong interest and potential for success [58] Volixibat - **Indications**: Targeting primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) [78][87] - **Unique Approach**: Using pruritus as a primary endpoint for PSC, which has no approved therapies, represents a novel strategy [78][79] - **Market Potential**: Approximately 30,000 PSC patients in the U.S., with two-thirds experiencing pruritus, indicating a substantial launch population [81][83] Strategic Focus and Future Outlook - **Investment Strategy**: The company aims to balance investments in pipeline development while maintaining a positive cash flow position [98] - **Market Position**: Mirum expects to have a competitive edge in the PSC market due to the lack of approved therapies, allowing for a strong market presence for several years [96][94] - **Long-term Vision**: The company is focused on building value through new medicines and disciplined business development efforts [98][99] Conclusion - Mirum Pharmaceuticals is positioned for significant growth with a robust pipeline and strong commercial performance. The focus on rare diseases and innovative treatment approaches, combined with a solid financial outlook, presents a compelling investment opportunity.

Core Insights - Amicus is a rare disease-focused biotech company with three programs, each having a potential market opportunity of $1 billion, currently at different development stages [1] - The company is expected to turn profitable in the second half of the year and maintains a strong cash position [1] Product Performance - Galafold, the first approved product for Fabry disease, was launched in 2016 and is projected to achieve 10% to 15% growth this year, with sales exceeding $500 million [2] - Pombiliti, Opfolda, is in the early stages of its launch after receiving approval in 2023, indicating potential for future growth [2]

Core Viewpoint - Amicus Therapeutics will host a conference call on November 4, 2025, to discuss its financial results for the quarter ended September 30, 2025 [1]. Group 1: Conference Call Details - The conference call will take place at 8:30 a.m. ET [1]. - Participants must register online to access the call by phone, receiving a dial-in number and personal PIN after registration [2]. - A live audio webcast and related presentation materials will be available on the company's corporate website [2]. Group 2: Post-Event Information - An archived webcast and accompanying slides will be accessible on the company's website shortly after the live event concludes [3]. Group 3: Company Overview - Amicus Therapeutics is a global biotechnology company focused on developing high-quality medicines for rare diseases [4]. - The company emphasizes patient dedication and aims to advance a pipeline of innovative medicines [4].

Core Insights - Amicus Therapeutics reported strong quarterly results for Q2 2025, exceeding expectations in both GAAP revenue and non-GAAP earnings, with GAAP revenue of $154.7 million, a 22.1% increase year-over-year, and non-GAAP EPS of $0.01, significantly better than the estimated –$0.12 [1][2] Financial Performance - GAAP revenue reached $154.7 million, up from $126.7 million a year earlier, surpassing the analyst target of $146.7 million [1][2] - Non-GAAP EPS was $0.01, compared to an estimate of –$0.12 and a previous year EPS of $0.06, reflecting an 83.3% decline year-over-year [2] - Galafold revenue was $128.9 million, a 16.3% increase from $110.8 million in Q2 2024 [2][5] - Pombiliti + Opfolda revenue increased by 62.8% to $25.8 million, up from $15.9 million a year earlier [2][6] - Non-GAAP operating expenses rose to $127.8 million, a 55.7% increase from $82.1 million in the previous year [2][8] Business Focus and Strategy - Amicus Therapeutics specializes in treatments for rare diseases, particularly genetic disorders, with key products being Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease [3] - The company is focused on broadening patient access, securing regulatory approvals, and expanding into related rare disease therapies [4] - The majority of sales are driven by Galafold, which is now approved in over 40 countries, with high global patient demand [5] Recent Developments - The company licensed U.S. rights for DMX-200, a late-stage drug for focal segmental glomerulosclerosis, paying a $30 million upfront fee [7] - Operating expenses increased due to the licensing payment and ongoing investments in research and development [8] Financial Outlook - Amicus reaffirmed its 2025 revenue growth outlook of 15–22% at constant exchange rates, with Galafold projected to grow 10–15% and Pombiliti + Opfolda expected to increase 50–65% [9] - The company anticipates gross margin to normalize in the mid-80% range for 2025 and aims for positive GAAP net income in the second half of 2025 [9] Key Monitoring Points - Investors should watch for progress in new country launches for Pombiliti + Opfolda, patient onboarding, and any changes in operating expenses or regulatory landscapes that could impact growth [10]

Financial Data and Key Metrics Changes - Total net product sales for 2024 were $336.4 million, a significant increase from $178.9 million in 2023, representing an 88% year-over-year growth [18][20] - In Q4 2024, total net product sales reached $99.4 million, compared to $69.5 million in Q4 2023, marking a 43% increase [18][19] - The company ended 2024 with cash, cash equivalents, and investments of $293 million, an increase of approximately $7 million from the start of the year [20] Business Line Data and Key Metrics Changes - Lebmarly's total net product sales for 2024 were $213.3 million, reflecting a 50% increase compared to 2023 [19] - Bile acid medicines generated total net product sales of $123.1 million for 2024, with Q4 sales of $35 million, representing a 25% growth over Q4 2023 [19][20] Market Data and Key Metrics Changes - The company anticipates net product sales between $420 million and $435 million for 2025, indicating expected growth driven by strong demand for its medicines [9][20] - The market for Fragile X syndrome is estimated to have a total addressable market of over $1 billion, with a patient population of approximately 50,000 in the U.S. [30][32] Company Strategy and Development Direction - The strategic priorities for 2025 include expanding the global growth of commercial medicines, advancing the pipeline, selectively pursuing product acquisitions, and maintaining scientific and financial discipline [6][7] - The company aims to leverage its financial position to acquire rare disease products that present significant value creation opportunities [25][26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong demand for Lebmarly and bile acid medicines, expecting continued growth in 2025 [9][10] - The company is well-funded and expects to maintain positive cash flow while progressing toward multiple upcoming pipeline catalysts [20] Other Important Information - The FDA approved Citexley for cerebrotendinous xanthomatosis (CTX) in adults, which is expected to enhance promotional efforts and patient reach [9][10] - The company has expanded its pipeline with the addition of MRM-3379 for Fragile X syndrome, indicating a focus on high unmet needs in rare genetic neurology [11][17] Q&A Session Summary Question: Strategic question regarding capital allocation and business development - Management highlighted the unique position of the company in the rare disease market, allowing for potential acquisitions of valuable products [25][26] Question: Market penetration and competition for MRM-3379 - Management discussed the substantial upside in the market potential for Fragile X syndrome and the applicability of the mechanism in other conditions [30][32] Question: Alagille syndrome market penetration - Management estimated that approximately 40% of the eligible treatment population in the U.S. has been penetrated, indicating significant growth potential [36][38] Question: Impact of recent CTX approval on sales trajectory - Management expects a gradual increase in patient diagnoses and treatment conversions to Citexley, positively impacting sales [40][41] Question: Patient mix between Alagille syndrome and PFIC - Management confirmed that most Lebmarly patients are Alagille syndrome patients, with a notable increase in PFIC patient starts contributing to growth [46][47] Question: Commercial team expansion for expanded pruritus - Management indicated that no significant expansion of the commercial team is anticipated, as the same prescribing universe will be leveraged [49][50] Question: VISTA study enrollment and timeline for data - Management projected a six-month timeline for top-line data after enrollment completion for the VISTA study [68][69] Question: Interim data from the EXPAND study - Management confirmed that no interim analysis is planned for the EXPAND study, with a focus on completing enrollment by 2026 [73][74]